
Description
Protein S Polyclonal Antibody – Goat
Affinity’s Protein S Polyclonal Antibody – Goat is the base level of our Protein S antibody family. The purity of IgG is typically 90% and is provided in a solution of HEPES buffered saline containing 50% glycerol (v/v). The titre is essentially the same as the starting antiserum and each vial typically contains the amount of IgG recovered from one milliliter of antiserum. This Protein S Polyclonal Antibody – Goat is generally intended for use in applications such as immuno-precipitation, immuno-electrophoresis, immuno-depletion and activity neutralization assays.
Product Code: GAPS-IG
Retail Product Size: 0.5mg vial
Host Animal: Goat Anti-Human Protein S Polyclonal Antibody – Goat
Species Cross Reactivity: View Chart
Product Datasheet: Protein S PS Polyclonal Antibody, purified anti-human goat IgG
Description of Protein S
Protein S is a vitamin K-dependent glycoprotein produced in the liver, endothelium and megakaryocytes. The concentration of PS in plasma is ~25 μg/ml (~325 nM) where it acts as a cofactor in the anticoagulant activity of activated Protein C. A deficiency of Protein S (quantitative or qualitative) is a risk factor for vascular thrombosis. Protein S is expressed as a single chain molecule with a molecular weight of 77 kDa. The structure of PS is similar to many other vitamin-K dependent coagulation proteins, consisting of an N-terminal calcium binding domain of 10 γ-carboxyglutamic acid (gla) residues, followed by a thrombin-sensitive loop region and 4 EGF-like domains. The C-terminal domain does not contain the usual catalytic triad of a proenzyme, but seems instead to be involved in the binding of PS to C4b-binding protein (C4bp). Protein S binds to activated Protein C (APC) in the presence of calcium and negatively charged phospholipid surface to allow APC to proteolytically inactivate coagulation cofactors Va and VIIIa. Enzymatic regulation of PS cofactor activity is through cleavage of PS in the thrombin-sensitive loop region by thrombin or other enzymes, resulting in the loss of calcium binding properties and APC cofactor activity. Another regulatory mechanism is to reduce the availability of PS by the binding of PS to C4bp. In plasma, approximately 60% of Protein S circulates in non-covalent complex with C4bp, making it unavailable for APC cofactor activity. The binding of PS to C4bp may be important in localizing C4bp to damaged cell membranes where it may control activation of complement by the classical pathway1-3.
References and Review
- Broze GJ, Miletich JP; Biochemistry and Physiology of Protein C, Protein S and Thrombomodulin; in Hemostasis and Thrombosis, 3rd Edition, eds. RW Colman, J Hirsh, VJ Marder and EW Salzman, pp 259-276, J.B. Lippincott Co., Philadelphia PA, USA, 1994.
- Comp PC, Doray D, Patton D, Esmon CT; An Abnormal Plasma Distribution of Protein S Occurs in Functional Protein S Deficiency. Blood 67, pp 504-508, 1986.
- Schwalbe RA, Dahlback B, Nelsestuen GL; Independent Association of Serum Amyloid P Component, Protein S and Complement C4b with C4b-binding Protein and Subsequent Association of the Complex with Membranes; JBC 265, pp 21749-21757, 1990.
ebiomall.com






>
>
>
>
>
>
>
>
>
>
>
>
2.pgem-3zf (+) 双链dna对照模板 0.2g/l,试剂盒配套试剂。
3.m13(-21)引物 tgtaaaacgacggccagt,3.2μmol/l,即3.2pmol/μl,试剂盒配套试剂。
4.dna测序模板 可以是pcr产物、单链dna和质粒dna等。模板浓度应调整在pcr反应时取量1μl为宜。本实验测定的质粒dna,浓度为0.2g/l,即200ng/μl。
5.引物 需根据所要测定的dna片段设计正向或反向引物,配制成3.2μmol/l,即3.2pmol/μl。如重组质粒中含通用引物序列也可用通用引物,如m13(-21)引物,t7引物等。
6.灭菌去离子水或三蒸水。
7.0.2ml或和0.5ml的pcr管 盖体分离,pe公司产品。
8.3mol/l 醋酸钠(ph5.2) 称取40.8g naac·3h2o溶于70ml蒸馏水中,冰醋酸调ph至5.2,定容至100ml,高压灭菌后分装。
9.70%乙醇和无水乙醇。
10.naac/乙醇混合液 取37.5ml无水乙醇和2.5ml 3mol/l naac混匀,室温可保存1年。
11.pop 6测序胶 abi产品。
12.模板抑制试剂(tsr) abi产品。
13.10×电泳缓冲液 abi产品。
14.abi prism 310型全自动dna测序仪。
15.2400型或9600型pcr仪。
16.台式冷冻高速离心机。
17.台式高速离心机或袖珍离心机。向左转|向右转
时间:2016-7-1518:51 来源:测序中国
新药研发是场艰难、昂贵的持久战。以美国的流程为例,3-6年的时间从约5,000-10,000个化合物中海选出250个选手进入临床前研究:基于细胞水平的体外实验检测化合物的毒性、致癌性和致突变的作用,经过筛选的化合物化学改性,以提高靶向特异性、效力、化学和代谢稳定性、水溶性等药理学参数;此外,先导化合物还需在实验室内开展动物实验,对化合物在动物体内的吸收、分布、代谢和排泄进行药代动力学试验。层层筛选后,需获得监管机构的新药临床研究申请批复方可开展人体试验。
通常会有5个种子选手进入临床研究,在20-100名不等的健康志愿者和患者小样本人群中确定最大耐受剂量、药代动力学和药效学的1期,约50-60%的试验药物可进入100-500人的2期研究。接下来,约30-35%的试验药物进入1,000-5,000的大规模3期证明疗效。顺利的话,整个临床研究将耗时6-7年。临床研究完成之后需将相关数据材料交给政府部门予以审核,最终只有1个幸运儿跨过独木桥获得国家级别的批准,进入规模生产。
利用BRCA1或BRCA2作为靶点的研究也毫无疑问地经历了上述过程。FarmerH等在05年使用BRCA1或BRCA2缺陷的胚胎干细胞研究细胞的生存情况,首次证实BRCA1或BRCA2功能异常的胚胎干细胞对PARP酶抑制剂非常敏感,导致染色体不稳定、细胞周期停滞和凋亡;证实BRCA和PARP两条不同的通路合作修复DNA损伤。这意味着靶向抑制特定的DNA修复通路可能可以设计特定的肿瘤治疗靶点。同年,BryantHE等利用PARP1-/-小鼠和BRCA2缺陷的细胞株,得出与FarmerH类似的结论,一个新概念的肿瘤治疗方案由此产生。
08年,EversB等首次在BRCA2缺陷的小鼠乳腺肿瘤细胞系评估AZD2281、顺铂单药以及联合使用的协同效果,发现无论AZD2281单药还是两种药物的组合,对BRCA2缺陷型细胞显示出增效的细胞毒性。
正是在这些强烈的临床前证据下,利用DNA修复的合成致死机制,第一款靶向药物AZD2281启动了一系列临床研究,逐步夯实了奥拉帕利作为卵巢癌领域第一个口服靶向药的基石地位。
奥拉帕利临床研究一览表
多篇高影响因子文献反复验证了奥拉帕利作为第一个使用合成致死机制的口服靶向药,逐步摸索锁定有效人群、最佳治疗阶段、用药方式。2014年12月奥拉帕利迎来美国适应症,紧接着2015年2月获得欧盟适应症,亚洲地区澳门2015年9月获批。
美国适应症:奥拉帕利可单药治疗携带致病或疑似致病的胚系BRCA突变(根据FDA批准的检测方法)、经三线或更多化疗的晚期卵巢癌患者。
欧盟/澳门适应症:对含铂化疗敏感(完全缓解或部分缓解),铂敏感复发、BRCA突变的(胚系和/或体细胞)高级别上皮性卵巢癌、输卵管癌或原发性腹膜癌的成年患者,奥拉帕利可作为其维持治疗阶段的单药治疗。
其它PARP抑制剂的研发进度在今年也不断刷屏,希望为癌症患者带来新曙光。
时间:2016-7-1518:51 来源:测序中国

